Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: difference between HCV genotypes 1b and 2

Seki, Nobuyoshi; Sugita, Tomonori; Aida, Yuta; Itagaki, Munenori; Ishiguro, Haruya; Sutoh, Satoshi; Abe, Hiroshi; Tsubota, Akihito; Matsushima, Masato; Aizawa, Yoshifusa

doi:10.1007/s12072-014-9572-2

Cited by 9 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oliveira et al [16] and Seki et al [17] agreed with our results and recorded raised Apo A2 level in HCC patients to reach 65 and 98 mg/dL, respectively. Zhang et al [18], Petit et al [19] and Perlemuter et al [20] recorded Apo A2 high level to reach 160, 142 and 180 mg/dL respectively in cirrhotic patients, which agreed with our results.…”

Section: Discussionsupporting

confidence: 91%

Evaluation of serum protein markers in diagnosis of hepatocellular carcinoma and carcinogenesis risk assessment in chronic liver disease patients

Hegazy¹,

Eissa²,

Sorour³

et al. 2017

APJTD

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Evaluation of serum protein markers in diagnosis of hepatocellular carcinoma and carcinogenesis risk assessment in chronic liver disease patients

Hegazy¹,

Eissa²,

Sorour³

et al. 2017

APJTD

View full text Add to dashboard Cite

“… 19 – 21 Furthermore, posttreatment increases in serum total and LDL-cholesterol levels were observed in HCV patients with SVR. 14 , 22 However, studies with IFN-based therapy were limited in terms of evaluating dynamic changes in serum biochemical parameters of lipid metabolism during treatment, as administration of exogenous IFN-α/β in the setting of treatment for chronic HCV infection and other conditions can reduce LDL-cholesterol levels and raise triglyceride levels. 23 – 25 …”

Section: Introductionmentioning

confidence: 99%

Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b

et al. 2018

View full text Add to dashboard Cite

Background/AimsChanges in lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antiviral therapy have been reported in recent years. However, the clinical aspects of disturbed lipid metabolism in chronic HCV infection have not been fully elucidated.MethodsDynamic changes in serum total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol and apolipoprotein levels in patients infected with HCV genotype 1b were examined during combination therapy with daclatasvir (DCV) and asunaprevir (ASV).ResultsTotal, LDL−, and HDL-cholesterol levels increased rapidly and persistently after week 4. Apolipoprotein (apo) A-I, apo B, apo C-II, and apo C-III levels were significantly higher at week 4 than at week 0. In contrast, apo A-II and apo E levels were significantly lower. The differences in LDL− and HDL-cholesterol levels were positively correlated with those of apo B and apo A-I, respectively. Interestingly, in patients with non-sustained virological response, these cholesterol levels decreased rapidly after viral breakthrough or viral relapse. Furthermore, similar changes were observed for apo A-I, apo B and apo C-III levels.ConclusionsClearance of HCV using combination therapy with DCV and ASV results in rapid changes in serum lipid profiles, suggesting an influence of HCV infection on disturbed lipid metabolism.

show abstract

“…Thus, in this study, we examined serum lipid profiles in Japanese patients with HCV G1b, which is the most prevalent HCV genotype in Japan [ 12 , 13 ]. Then, we describe the serum TG profiles of patients with active HCV G1b infection and further clarify the impact of HCV G1b infection on VLDL sub-fractions.…”

Section: Introductionmentioning

confidence: 99%

Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions

Nagano

Seki

Tomita

et al. 2015

IJMS

Self Cite

View full text Add to dashboard Cite

Reduced low-density lipoprotein (LDL) cholesterol level is a characteristic feature of dyslipidemia in chronic hepatitis C virus (HCV) infection. However, abnormality in serum triglyceride (TG) has not been fully investigated. To clarify the impact of HCV genotype 1b (G1b) infection and advanced fibrosis on serum TG profiles, TG concentrations in lipoprotein fractions were examined in fasting sera from 185 subjects with active or cleared HCV infection by high-performance liquid chromatography. Serum lipoproteins were fractionated into four classes: chylomicron, very low-density lipoprotein (VLDL), LDL, and high-density lipoprotein (HDL). Then, the significance of HCV G1b infection on TG levels in each lipoprotein fraction was determined using multiple regression models. We found that active HCV G1b infection was positively associated with high HDL-TG levels and low VLDL-TG levels, independent of other factors included in the regression model. In VLDL sub-fractions, active HCV infection was only found to be associated with low levels of large VLDL-TG. Similarly, advanced liver fibrosis in chronic HCV G1b infection was associated with high levels of LDL-TG, HDL-TG, and small VLDL-TG, independent of other clinical factors. These findings indicate that active HCV G1b infection and advanced fibrosis are closely associated with abnormal serum TG profiles.

show abstract

Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: difference between HCV genotypes 1b and 2

Cited by 9 publications

References 30 publications

Evaluation of serum protein markers in diagnosis of hepatocellular carcinoma and carcinogenesis risk assessment in chronic liver disease patients

Evaluation of serum protein markers in diagnosis of hepatocellular carcinoma and carcinogenesis risk assessment in chronic liver disease patients

Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b

Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions

Contact Info

Product

Resources

About